Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) shares fell 5.2% on Wednesday following insider selling activity. The company traded as low as $16.00 and last traded at $16.25, with a volume of 809,920 shares trading hands. The stock had previously closed at $17.15.

Specifically, CFO Andrew P. Smith sold 1,766 shares of the company’s stock in a transaction on Tuesday, November 15th. The shares were sold at an average price of $15.58, for a total transaction of $27,514.28. Following the sale, the chief financial officer now owns 348 shares of the company’s stock, valued at $5,421.84. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Daniel P. Getman sold 20,000 shares of the company’s stock in a transaction on Tuesday, November 29th. The shares were sold at an average price of $16.86, for a total transaction of $337,200.00. Following the sale, the director now directly owns 16,201 shares in the company, valued at approximately $273,148.86. The disclosure for this sale can be found here. 3.31% of the stock is currently owned by insiders.

A number of research firms recently issued reports on SCMP. Jefferies Group reaffirmed a “hold” rating and set a $16.00 price target (up previously from $14.00) on shares of Sucampo Pharmaceuticals in a research note on Friday, November 11th. Zacks Investment Research raised shares of Sucampo Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, August 8th. Mizuho downgraded shares of Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $13.00 price target on the stock. in a research note on Thursday, August 4th. Vetr downgraded shares of Sucampo Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $14.00 price target on the stock. in a research note on Monday, September 19th. Finally, Northland Securities began coverage on shares of Sucampo Pharmaceuticals in a research note on Wednesday, September 7th. They set an “outperform” rating and a $15.00 price target on the stock. Five equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $17.33.

The company has a market cap of $695.79 million, a PE ratio of 54.90 and a beta of 1.62. The company has a 50-day moving average price of $13.49 and a 200-day moving average price of $12.15.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its quarterly earnings results on Wednesday, November 9th. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.26 by $0.02. Sucampo Pharmaceuticals had a net margin of 6.29% and a return on equity of 44.19%. The firm had revenue of $57.90 million for the quarter, compared to analysts’ expectations of $51.30 million. During the same quarter last year, the company earned $0.16 EPS. The firm’s revenue for the quarter was up 73.4% compared to the same quarter last year. On average, equities analysts predict that Sucampo Pharmaceuticals Inc. will post $1.22 EPS for the current year.

A number of large investors have recently added to or reduced their stakes in SCMP. BlackRock Fund Advisors boosted its stake in Sucampo Pharmaceuticals by 3.1% in the first quarter. BlackRock Fund Advisors now owns 1,630,036 shares of the biopharmaceutical company’s stock worth $17,816,000 after buying an additional 48,420 shares in the last quarter. Quantbot Technologies LP raised its position in shares of Sucampo Pharmaceuticals by 850.4% in the second quarter. Quantbot Technologies LP now owns 14,903 shares of the biopharmaceutical company’s stock worth $163,000 after buying an additional 13,335 shares during the last quarter. Princeton Alpha Management LP purchased a new position in shares of Sucampo Pharmaceuticals during the second quarter worth $138,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Sucampo Pharmaceuticals during the second quarter worth $207,000. Finally, Boston Partners raised its position in shares of Sucampo Pharmaceuticals by 36.6% in the second quarter. Boston Partners now owns 238,519 shares of the biopharmaceutical company’s stock worth $2,617,000 after buying an additional 63,965 shares during the last quarter. 41.12% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece was reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2016/12/01/sucampo-pharmaceuticals-inc-scmp-trading-down-5-2-following-insider-selling.html.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It operates through development and commercialization of pharmaceutical products segment. Its operations are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts operations in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, the United Kingdom.

5 Day Chart for NASDAQ:SCMP

Receive News & Stock Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.